Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Children's Hospital & Research Center Oakland
ClinicalTrials.gov Identifier:
NCT01556009
First received: March 14, 2012
Last updated: August 5, 2015
Last verified: August 2015
  Purpose

The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).


Condition Intervention Phase
Basal Cell Nevus Syndrome
Gorlin's Syndrome
Drug: Vismodegib
Drug: Aminolevulinic acid %20 topical solution
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas

Resource links provided by NLM:


Further study details as provided by Children's Hospital & Research Center Oakland:

Primary Outcome Measures:
  • Time to recurrence to baseline SEB burden following 7 months of continuous vismodegib treatment. [ Time Frame: A Data Safety Monitoring Board (DSMB) will review results for an interim analysis when 12 subjects have completed 28 months. ] [ Designated as safety issue: Yes ]

    Primary:

    i. To compare the efficacy of (i) intermittent vismodegib vs. (ii) the efficacy of photodynamic therapy (PDT) in preventing the return of the burden of surgically eligible BCCs (SEBs) to baseline level following 7 months of continuous vismodegib therapy.

    ii. To compare the cumulative diameter (burden) of SEBs in patients treated intermittently with vismodegib vs. with photodynamic therapy (PDT).



Secondary Outcome Measures:
  • The cumulative diameter (burden) of SEBs in patients treated intermittently with vismodegib vs PDT during months 8-28 maintenance period. [ Time Frame: A Data Safety Monitoring Board (DSMB) will review results for an interim analysis when 12 subjects have completed 28 months. ] [ Designated as safety issue: Yes ]

    i. To assess the safety of intermittent vismodegib in patients with multiple BCCs (BCNS and non-BCNS) during months 8-28.

    ii. To assess resistance of SEBs to treatments in patients with multiple BCCs (BCNS and non-BCNS) treated intermittently during months 8-28.

    iii. To assess the degree of reduction of SEBs after 7 months of continuous daily vismodegib therapy.

    iv. To conduct an exploratory evaluation in non-BCNS patients with multiple BCCs (high burden of disease) of the efficacy and tolerability of intermittent vismodegib vs PDT



Estimated Enrollment: 24
Study Start Date: April 2012
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Drug (Vismodegib)
Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
Drug: Vismodegib
150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
Other Names:
  • Erivedge
  • GDC-0449
Active Comparator: Aminolevulinic acid %20 topical solution
Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
Drug: Aminolevulinic acid %20 topical solution
20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
Other Name: Levulan

Detailed Description:

This is a Phase II, 28 month, randomized, two arm multicenter clinical study design. During the initial 7 months of the study, all 24 subjects will receive vismodegib, 150mg/day. They then will be randomized in a 1:1 ratio to receive intermittent vismodegib, 150 mg/day, during months 10-13, 16-19, and 22-25 or to receive treatment with PDT at month 10 and at three month intervals thereafter. The safety and efficacy of intermittent vismodegib and of PDT will be assessed at the time of the subjects' visits to the Study Center and at the time of telephone contacts. A Data Safety Monitoring Board (DSMB) will review results for an interim analysis when 12 subjects have completed 28 months. The DSMB review will focus on adverse events and efficacy results. Subjects will be monitored for the presence of surrogate endpoint biomarkers (SEBs) at each Study visit.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The subject:

  • has had diagnosed at least 10 SEB (of diameter 3 mm diameter or greater on the nose or periorbital skin, 5 mm or greater elsewhere on the face, or 9 mm or greater on non-facial areas excluding the skin below the knees) during the two years before study entry.
  • meet diagnostic criteria for basal cell nevus syndrome
  • is willing to abstain from application of non-study topical medications to the skin for the duration of the study. For example, topical preparations containing corticosteroids (other than Triamcinolone applied no more than 6x/month).
  • is willing to forego treatment of BCCs unless the BCCs are documented by Study Investigators, preferably on two separate visits, except when the PSCP believes that delay in treatment potentially might compromise the health of the subject.
  • has normal laboratory tests as defined by the following: Normal hematopoietic capacity, Normal hepatic function: AST and ALT greater than or equal to 2x the upper limit of normal (ULN) Total bilirubin within normal range 0.20 mg/dl to 1.50 mg/dl or within 3x ULN for patients with Gilbert's disease Normal renal function: normal serum creatinine or measured creatinine clearance less than 50 mL/minute. Fasting cholesterol greater than or equal to 220 untreated
  • be willing to not donate blood or semen for three months following discontinuation of Study medications.
  • is willing to avoid pregnancy in his partner as defined by the following: Male subject is willing to use a latex condom during the study and for 3 months after the last dose during sexual contact with a female of childbearing potential, even if he has had a successful vasectomy. His partner must also use a form of birth control

Exclusion Criteria:

The subject:

  • has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study. Specifically these include the use of: (i) glucocorticoids (other than Triamcinolone on no more than 36 days during the six months prior to study entry) to more than 5% of the skin (ii) retinoids systemically or topically to more than 5% of the skin during the six months prior to study entry; (iii) alpha-hydroxy acids to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod systemically or topically to the skin above the knees during the six months prior to study entry. (v) treatment with systemic chemotherapy within one year prior to starting study medication.
  • has a history of hypersensitivity to any of the ingredients in the study medication formulations.
  • is unable to return for follow-up visits and tests.
  • has uncontrolled systemic disease, including known HIV positive patients.
  • has history of congestive heart failure.
  • has uncontrolled hypocalcemia, hypomagnesemia, or hypokalemia
  • has clinically important history of liver disease, including viral or hepatitis, current alcohol abuse, or cirrhosis.
  • has any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study.
  • has a history of invasive cancer within the past five years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or CLL Stage 0.
  • has current, recent (within 4 weeks of Day 1), or planned participation in an experimental drug study while enrolled in this study.
  • is a female who is pregnant, plans to ever to become pregnant, capable of becoming pregnant or is breast feeding.
  • is a male who is unwilling or unable to comply with pregnancy prevention measures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01556009

Locations
United States, California
Children's Hospital Oakland Research Institiute
Oakland, California, United States, 94609
Children's Hospital Research Center Oakland
Oakland, California, United States, 94609
United States, New York
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Children's Hospital & Research Center Oakland
Genentech, Inc.
Investigators
Principal Investigator: Ervin Epstein, MD Children's Hospital Research Institute
  More Information

No publications provided

Responsible Party: Children's Hospital & Research Center Oakland
ClinicalTrials.gov Identifier: NCT01556009     History of Changes
Other Study ID Numbers: 2011-077, ML28244
Study First Received: March 14, 2012
Last Updated: August 5, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital & Research Center Oakland:
Basal Cell Carcinoma
Photodynamic Therapy

Additional relevant MeSH terms:
Basal Cell Nevus Syndrome
Carcinoma, Basal Cell
Hamartoma Syndrome, Multiple
Syndrome
Abnormalities, Multiple
Bone Cysts
Bone Diseases
Bone Diseases, Developmental
Carcinoma
Congenital Abnormalities
Cysts
Disease
Genetic Diseases, Inborn
Hamartoma
Jaw Cysts
Jaw Diseases
Musculoskeletal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Basal Cell
Neoplasms, Glandular and Epithelial
Neoplasms, Multiple Primary
Neoplastic Syndromes, Hereditary
Odontogenic Cysts
Pathologic Processes
Stomatognathic Diseases
Aminolevulinic Acid
Pharmaceutical Solutions
Dermatologic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 26, 2015